DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112 · readout in 884 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo Co., Ltd., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

600estimated

Sites

252

Countries

Australia, Austria, Belgium +20

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-03-27

actual

When the study began enrolling

Primary completion

2029-01-19

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-02-19

estimated

The whole study's end, after follow-up

First posted

2025-05-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Endometrial Cancer

Interventions

Drug: Trastuzumab deruxtecan — also filed as DS-8201a, T-DXd
Drug: Rilvegostomig
Drug: Pembrolizumab — also filed as Keytruda
Drug: Carboplatin — also filed as Carbomedac, Carbosin, Paraplatin
Drug: Paclitaxel — also filed as Anzatax, Ebetaxel, Oncotaxel, Paclitax, Paclitaxin, Paxene, Taxol
Drug: Docetaxel — also filed as Docirena, Taxceus, Taxotere

Primary outcome

what the primary-completion date above is the date OF

Progression-free survival (PFS), as assessed by BICR

measured Until progression or death due to any cause (assessed up to approximately 45 months).

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed